Global Raynauds Disease Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Raynauds Disease treatment during 2019. Clinical development activities are being undertaken by more than 5 companies including Allergan Plc , Apricus Biosciences Inc, Exodos Life Sciences Limited Partnership, Pfizer Inc and others.
A Significant contribution to the Raynauds Disease pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Raynauds Disease pipeline included 4 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Raynauds Disease condition and increased access to investments is encouraging growth of Raynauds Disease drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Raynauds Disease drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Raynauds Disease therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Raynauds Disease pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Raynauds Disease. Further, orphan drug status, fast track designation, grants awarded and other special status for Raynauds Disease pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Raynauds Disease pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Raynauds Disease Pipeline candidates-
A Significant contribution to the Raynauds Disease pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Raynauds Disease pipeline included 4 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Raynauds Disease condition and increased access to investments is encouraging growth of Raynauds Disease drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Raynauds Disease drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Raynauds Disease therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Raynauds Disease pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Raynauds Disease. Further, orphan drug status, fast track designation, grants awarded and other special status for Raynauds Disease pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Raynauds Disease pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Raynauds Disease Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Raynauds Disease drugs
- Late phase: Phase 3 and in-approval Raynauds Disease drugs
- Company overview
- Snapshot
- Raynauds Disease therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Raynauds Disease- Disease Overview
2.2 Raynauds Disease- Pipeline Snapshot
2.3 Raynauds Disease- Pipeline Drugs by Phase
2.4 Raynauds Disease- Pipeline Drugs by Company
2.5 Raynauds Disease- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Allergan Plc Raynauds Disease Drug Pipeline, H2- 2019
3.2 Apricus Biosciences Inc Raynauds Disease Drug Pipeline, H2- 2019
3.3 Exodos Life Sciences Limited Partnership Raynauds Disease Drug Pipeline, H2- 2019
3.4 Pfizer Inc Raynauds Disease Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Raynauds Disease- Phase 1 Drug Details
4.2 Raynauds Disease- Phase 1 Drug Overview
4.3 Raynauds Disease- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Raynauds Disease- Phase 2 Drug Details
5.2 Raynauds Disease- Phase 2 Drug Overview
5.3 Raynauds Disease- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Raynauds Disease- Phase 3 Drug Details
6.2 Raynauds Disease- Phase 3 Drug Overview
6.3 Raynauds Disease- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Raynauds Disease- Pre-clinical Phase Drug Details
7.2 Raynauds Disease- Pre-clinical Phase Drug Overview
7.3 Raynauds Disease- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Raynauds Disease- Disease Overview
2.2 Raynauds Disease- Pipeline Snapshot
2.3 Raynauds Disease- Pipeline Drugs by Phase
2.4 Raynauds Disease- Pipeline Drugs by Company
2.5 Raynauds Disease- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Allergan Plc Raynauds Disease Drug Pipeline, H2- 2019
3.2 Apricus Biosciences Inc Raynauds Disease Drug Pipeline, H2- 2019
3.3 Exodos Life Sciences Limited Partnership Raynauds Disease Drug Pipeline, H2- 2019
3.4 Pfizer Inc Raynauds Disease Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Raynauds Disease- Phase 1 Drug Details
4.2 Raynauds Disease- Phase 1 Drug Overview
4.3 Raynauds Disease- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Raynauds Disease- Phase 2 Drug Details
5.2 Raynauds Disease- Phase 2 Drug Overview
5.3 Raynauds Disease- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Raynauds Disease- Phase 3 Drug Details
6.2 Raynauds Disease- Phase 3 Drug Overview
6.3 Raynauds Disease- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Raynauds Disease- Pre-clinical Phase Drug Details
7.2 Raynauds Disease- Pre-clinical Phase Drug Overview
7.3 Raynauds Disease- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
